BioCentury | May 4, 2020

Stemline takeout gives Menarini U.S. oncology beachhead

Although Menarini will gain a modest-selling drug by acquiring Stemline for up to $677 million, the Italian biopharma will also establish a U.S. oncology presence as its cancer pipeline matures. The deal gives Menarini Group...
BioCentury | May 1, 2020
Distillery Therapeutics

Disrupting hypoxia signaling to treat a muscular dystrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy The PI3K-mTOR pathway inhibitors could treat facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle wasting disorder caused by inappropriate DUX4 expression, by disrupting the hypoxia signaling pathway. In a DUX4-expressing...
BioCentury | Apr 14, 2020

Expanded deal with Kyowa could give MEI cash through drug approval

Building on a 2018 deal in Japan, MEI Pharma granted Kyowa Kirin ex-U.S. rights to its PI3Kδ inhibitor ME-401 in an expanded partnership that could shore up the San Diego-based biotech’s balance sheet through a...
BioCentury | Feb 28, 2020

Verastem raises $100M, plots path forward with targeted cancer combo

Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at...
BioCentury | Jan 24, 2020

iOnctura taps European syndicate for series A to bring two ‘best-in-class’ programs to the clinic

On the strength of its new €15 million ($16.6 million) series A round, iOnctura believes it can have two best-in-class oncology candidates in the clinic within a year. Created in 2017 by former Merck KGaA...
BC Extra | Jan 13, 2020
Company News

MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb

The first major deal under the watch of MorphoSys’ new CEO Jean-Paul Kress triples the German biotech’s cash position through a global partnership with Incyte to develop and commercialize blood cancer therapy tafasitamab. While the...
BioCentury | Jan 9, 2020
Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex...
BioCentury | Jan 1, 2020

Fewer FDA approvals in 2019, but a basket of firsts

While the year held fewer approvals of new molecular entities than 2018, it was not short of major achievements. FDA greenlit several drugs with innovative modalities, against novel targets and for diseases that have long...
BioCentury | Dec 14, 2019
Product Development

BCMA programs begin to find their niches

As CAR Ts, bispecifics and ADCs targeting BCMA battle it out in multiple myeloma, the question is not which modality will win, but whether they can fill different niches in the treatment landscape. The safety...
BioCentury | Dec 13, 2019
Politics, Policy & Law

Novartis’ Narasimhan calls for value-based pricing--and access

Novartis CEO Vas Narasimhan believes drug prices and access should be based on value. He’s in favor of the use of cost-effectiveness assessments to justify drug prices -- which creates winners and losers -- and...
Items per page:
1 - 10 of 873